These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19483105)

  • 1. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
    Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
    Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
    Walker T; Mitchell C; Park MA; Yacoub A; Graf M; Rahmani M; Houghton PJ; Voelkel-Johnson C; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):342-55. PubMed ID: 19483104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
    Park MA; Zhang G; Martin AP; Hamed H; Mitchell C; Hylemon PB; Graf M; Rahmani M; Ryan K; Liu X; Spiegel S; Norris J; Fisher PB; Grant S; Dent P
    Cancer Biol Ther; 2008 Oct; 7(10):1648-62. PubMed ID: 18787411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
    J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
    Tang Y; Yacoub A; Hamed HA; Poklepovic A; Tye G; Grant S; Dent P
    Cancer Biol Ther; 2012 May; 13(7):567-74. PubMed ID: 22406992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
    Park MA; Reinehr R; Häussinger D; Voelkel-Johnson C; Ogretmen B; Yacoub A; Grant S; Dent P
    Mol Cancer Ther; 2010 Aug; 9(8):2220-31. PubMed ID: 20682655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
    Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
    J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
    Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
    Park MA; Mitchell C; Zhang G; Yacoub A; Allegood J; Häussinger D; Reinehr R; Larner A; Spiegel S; Fisher PB; Voelkel-Johnson C; Ogretmen B; Grant S; Dent P
    Cancer Res; 2010 Aug; 70(15):6313-24. PubMed ID: 20631069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
    Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
    Wei Y; Kadia T; Tong W; Zhang M; Jia Y; Yang H; Hu Y; Tambaro FP; Viallet J; O'Brien S; Garcia-Manero G
    Clin Cancer Res; 2010 Aug; 16(15):3923-32. PubMed ID: 20538760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
    World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
    Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
    Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
    Sajithlal GB; Hamed HA; Cruickshanks N; Booth L; Tavallai S; Syed J; Grant S; Poklepovic A; Dent P
    Mol Pharmacol; 2013 Oct; 84(4):562-71. PubMed ID: 23877009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
    Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.